Eloxx Pharmaceuticals Inc.

4.58-0.2000-4.18%Vol 31.28K1Y Perf 2 687.17%
Oct 4th, 2023 15:59 DELAYED
BID4.50 ASK5.18
Open4.66 Previous Close4.78
Pre-Market- After-Market4.79
 - -  0.21 4.59%
Target Price
3.00 
Analyst Rating
Strong Buy 1.00
Potential %
-34.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
31.33 
Earnings Rating
Sell
Market Cap12.61M 
Earnings Date
9th Nov 2023
Alpha-0.04 Standard Deviation0.41
Beta2.64 

Today's Price Range

4.535.09

52W Range

1.7010.90

5 Year PE Ratio Range

-2.00-1.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.85%
1 Month
-11.48%
3 Months
20.71%
6 Months
46.86%
1 Year
2 687.17%
3 Years
78.36%
5 Years
-68.72%
10 Years
-

TickerPriceChg.Chg.%
ELOX4.58-0.2000-4.18
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.20
0.87
7.42
-21.90
Leverage Ratio 13.60
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-1.54-1.96-27.27
Q01 2023-2.55-2.88-12.94
Q04 2022-2.97-2.921.68
Q03 2022-4.40-3.6018.18
Q02 2022-4.00-4.80-20.00
Q01 2022-3.60-5.20-44.44
Q04 2021-4.80-5.60-16.67
Q03 2021-5.60-4.4021.43
Earnings Per EndEstimateRevision %Trend
9/2023 QR-1.97-4.23Negative
12/2023 QR-1.4340.42Positive
12/2023 FY-7.915.27Positive
12/2024 FY-7.3915.45Positive
Next Report Date9th Nov 2023
Estimated EPS Next Report-1.97
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume31.28K
Shares Outstanding2.75K
Shares Float2.20M
Trades Count327
Dollar Volume149.82K
Avg. Volume321.11K
Avg. Weekly Volume14.70K
Avg. Monthly Volume26.38K
Avg. Quarterly Volume922.25K

Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) stock closed at 4.78 per share at the end of the most recent trading day (a 0.42% change compared to the prior day closing price) with a volume of 30.14K shares and market capitalization of 12.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Eloxx Pharmaceuticals Inc. CEO is Gregory Williams.

The one-year performance of Eloxx Pharmaceuticals Inc. stock is 2687.17%, while year-to-date (YTD) performance is 162.64%. ELOX stock has a five-year performance of -68.72%. Its 52-week range is between 1.6959 and 10.9, which gives ELOX stock a 52-week price range ratio of 31.33%

Eloxx Pharmaceuticals Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 6.31, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -113.38%, a ROC of -145.97% and a ROE of -364.24%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Eloxx Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.97 for the next earnings report. Eloxx Pharmaceuticals Inc.’s next earnings report date is 09th Nov 2023.

The consensus rating of Wall Street analysts for Eloxx Pharmaceuticals Inc. is Strong Buy (1), with a target price of $3, which is -34.50% compared to the current price. The earnings rating for Eloxx Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eloxx Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eloxx Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.73, ATR14 : 0.51, CCI20 : -72.73, Chaikin Money Flow : -0.09, MACD : -0.16, Money Flow Index : 58.36, ROC : -18.71, RSI : 44.52, STOCH (14,3) : 18.24, STOCH RSI : 0.68, UO : 36.37, Williams %R : -81.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eloxx Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Eloxx Pharmaceuticals Inc.

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis.

CEO: Gregory Williams

Telephone: +1 781 577-5300

Address: 950 Winter Street, Waltham 02451, MA, US

Number of employees: 29

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

Bearish Bullish

50%50%

 

News

Stocktwits